Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
BDTX Stock Chart & Stats
$2.67
-$0.07(-3.30%)
At close: 4:00 PM EST
$2.67
-$0.07(-3.30%)
Day’s Range― - ―
52-Week Range$1.20 - $4.94
Previous CloseN/A
Volume170.82K
Average Volume (3M)1.49M
Market Cap
$152.12M
Enterprise Value$200.93M
Total Cash (Recent Filing)$135.50M
Total Debt (Recent Filing)$16.04M
Price to Earnings (P/E)7.4
Beta2.06
Next Earnings
Mar 18, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding56,974,915
10 Day Avg. Volume1,021,162
30 Day Avg. Volume1,492,292
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.89
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit2.87
Enterprise Value/Ebitda11.46
Forecast
1Y Price Target
$8.25Price Target Upside208.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.45
Revenue Forecast (FY)$70.00M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe confirmed CNS ORR of 86% significantly outperformed expectations and supports best-in-class CNS activity.
Financial PerformanceBlack Diamond reported a net loss of $0.15 per share vs. prior estimated net loss of $0.24 per share, indicating better performance than expected.
Market PotentialSubstantial value creation for BDTX shares is anticipated on clinical updates, clarity on a registrational path, and a potential partnership.
Bears Say
Adverse EventsFrequency of AEs was higher than anticipated resulting in 77% rate of dose reductions.
Comparative EfficacySilevertinib's efficacy in PACC mutations does not appear as strong as firmonertinib in those patients without CNS metastases.
Sales ProjectionsLower sales projections were made due to risk adjusting for partnership requirements.
Black Diamond Therapeutics News
BDTX FAQ
What was Black Diamond Therapeutics’s price range in the past 12 months?
Black Diamond Therapeutics lowest stock price was $1.20 and its highest was $4.94 in the past 12 months.
What is Black Diamond Therapeutics’s market cap?
Black Diamond Therapeutics’s market cap is $152.12M.
When is Black Diamond Therapeutics’s upcoming earnings report date?
Black Diamond Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 81 days.
How were Black Diamond Therapeutics’s earnings last quarter?
Black Diamond Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.234 by $0.084.
Is Black Diamond Therapeutics overvalued?
According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued.
Does Black Diamond Therapeutics pay dividends?
Black Diamond Therapeutics does not currently pay dividends.
What is Black Diamond Therapeutics’s EPS estimate?
Black Diamond Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Black Diamond Therapeutics have?
Black Diamond Therapeutics has 56,974,915 shares outstanding.
What happened to Black Diamond Therapeutics’s price movement after its last earnings report?
Black Diamond Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.234. Following the earnings report the stock price went up 2.842%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics?
Currently, no hedge funds are holding shares in BDTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Black Diamond Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (208.99% Upside)
$8.25 (208.99% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 35.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.43%
12-Months-Change
Fundamentals
Return on Equity
19.23%
Trailing 12-Months
Asset Growth
14.39%
Trailing 12-Months
Company Description
Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
BDTX Stock 12 Month Forecast
Average Price Target
$8.25
▲(208.99% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Galectin Therapeutics
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Instil Bio
―
Ownership Overview
13.86% Insiders
17.23% Mutual Funds
36.25% Other Institutional Investors
27.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---